DRUG DELIVERY CARRIER, CONJUGATES AND COMPOSITION COMPRISING THE SAME AS WELL AS METHOD OF ADMINISTERING THE SAME

To provide novel drug delivery carriers and conjugates which can easily penetrate blood-brain barrier, blood-nerval barrier, blood-retinal barrier, blood-cerebrospinal fluid barrier and the like where only particular drugs can penetrate because of high drug permselectivity, and to provide compositio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MIYATA KANJIRO, MIZOGUCHI AKISUKE, YOKOTA TAKANORI, FUKUZATO YU, NISHIYAMA NOBUHIRO, MIZUSAWA HIDEHIRO, ISHII TAKEHIKO, KATAOKA KAZUNORI, ANRAKU YASUTAKA, MATSUMOTO TAMOTSU, NISHINA KAZUTAKA, KUWABARA HIROYA
Format: Patent
Sprache:eng ; jpn
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To provide novel drug delivery carriers and conjugates which can easily penetrate blood-brain barrier, blood-nerval barrier, blood-retinal barrier, blood-cerebrospinal fluid barrier and the like where only particular drugs can penetrate because of high drug permselectivity, and to provide compositions containing the same, as well as to provide methods of administering the same.SOLUTION: Provided is a composition for administering to a subject according to a dosage regimen which comprises a drug delivery carrier, the dosage regimen comprising (1) fasting the subject or inducing hypoglycaemia; (2) administering the composition to the subject; and (3) inducing the increase of blood glucose levels in the subject, the carrier having an outer surface which is modified by GLUT1 ligand. The carrier is a vesicle including the agent, and preferably 10 to 40 mol% of the polymer which forms the vesicle is modified by GLUT1 ligand.SELECTED DRAWING: Figure 1 【課題】薬剤透過選択性が高いために特定の薬剤しか透過することができない血液脳関門、血液神経関門、血液網膜関門、血液髄液関門等を容易に透過することができる新規薬剤送達用キャリア、コンジュゲート及びこれらを含んでなる組成物、並びにこれらの投与方法の提供。【解決手段】薬剤送達用のキャリアを含んでなる、投与計画に従って対象に投与するための組成物であって、前記投与計画は、(1)前記対象を絶食させるか低血糖を誘発させる工程、(2)前記対象に前記組成物を投与する工程、及び(3)前記対象において血糖値の上昇を誘発させる工程を含み、前記キャリアは、その外表面がGLUT1リガンドにより修飾されている、組成物。前記キャリアは前記薬剤を内包する小胞であって、前記小胞を形成する高分子の10〜40モル%がGLUT1リガンドにより修飾されていることが好ましい。【選択図】図1